





Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 3 of 23	Attorney Docket Number	OMRF 161 CIP	

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SAF	APR 20 2000	ALEXANDER, et al., "Anti-Ro/SS-A Antibodies in the Pathophysiology of Congenital Heart Block in Neonatal Lupus Syndrome, and Experimental Model," <i>Arth. And Rheum.</i> 35:176-189 (1992).	
SAF		ARBUCKLE, et al., "Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus," <i>Scand. J. Immunol.</i> 50(5):447-55 (1999).	
SAF		SANERJEE, et al., "Complete Nucleotide Sequence of the mRNA Coding for the N Protein of Vesicular Stomatitis Virus (New Jersey Serotype)," <i>Virology</i> 137:432-438 (1984).	
SAF		BARAKET, et al., "IgG Antibodies From Patients with Primary Sjogren's Syndrome and systemic Lupus Erythematosus Recognize Different Epitopes in 60-kD SSA/Ro Protein," <i>Clin. Exp. Immunol.</i> 89:38-45 (1992).	
SAF		BARAKET, et al., "Mapping of epitopes on U1 snRNP polypeptide A with synthetic peptides and autoimmune sera," <i>Clin. Exp. Immunol.</i> 86:71-78 (1991).	
SAF		BARAKET, et al., "Recognition of Synthetic Peptides of Sm-D Autoantigen by Lupus Sera," <i>Clin. Exp. Immunol.</i> 81:256-262 (1990).	
SAF		BEN-CHETRIT, et al., "Isolation and Characterization of a cDNA Encoding the 60-kD Component of the Human SS-A/Ro Ribonucleoprotein Autoantigen," <i>J. Clin. Inv.</i> 83:1284-1292 (1989).	
SAF		BLANK, et al., "Induction of Experimental Anti-phospholipid Syndrome Associated with SLE Following Immunization with Human Monoclonal Pathogenic Anti-DNA Idiotypic," <i>J. Autoimmunity</i> 5:495-509 (1992).	
SAF		BLANK, et al., "Induction of SLE-Like Disease in Naive Mice with a Monoclonal anti-DNA Antibody Derived from a Patient with Polymyositis carrying the 16/6 id," <i>J. Autoimmunity</i> 1:683-591 (1988).	
SAF		BLANK, et al., "Induction of Systemic Lupus Erythematosus in Naive Mice with T-cell Lines Specific for Human Anti-DNA Antibody SA-1 (16/6 Id+) and for Mouse Tuberculosis Antibody TB/68 (16/6 id+) <i>Clin. Immunol. Immunopathol.</i> 60:471-483 (1991).	

Examiner's Signature	<i>Sharon Feltz</i>	Date Considered	12/26/00
----------------------	---------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		<b>Complete if Known</b>	
		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 4 of 23	Attorney Docket Number	OMRF 161 CIP	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
STF		BLANK, et al., "Sex Hormone Involvement in the Induction of Experimental Systemic Lupus Erythematosus by a Pathogenic anti-DNA Idiotypic in Naive Mice," <i>J. Rheumatol.</i> 17:311-317 (1990).	
STF		BLANK, et al., "The Effect of the Immunomodulator Agent AS101 on Interleukin-2 Production in Systemic Lupus Erythematosus (SLE) Induced in Mice by Pathogenic Anti-DNA Antibody," <i>Clin. Exp. Immunol.</i> 79:443-447 (1990).	
STF		BRAY, et al., "Antibodies Against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and Two Pentapeptide Sequence Identities Between EBNA and Myelin Basic Protein," <i>Arch. Neurol.</i> 42:1798-1804 (1992).	
STF		BRAY, et al., "Epstein-Barr Virus Infection and Antibody Synthesis in Patients With Multiple Sclerosis," <i>Arch. Neurology</i> 40:406-408 (1983).	
STF		BUYON, "Neonatal Lupus Syndrome," <i>Curr. Opin. In Rheum.</i> 6:523-529 (1994).	
STF		CHAMBERS, et al., "Genomic Structure and Amino Acid Sequence domains of the Human La Autoantigen," <i>J. Biol. Chem.</i> 263:18043-18051 (1988).	
STF		CHAMBERS, et al., "Isolation and analysis of cDNA Clones Expressing Human Lupus La Antigen," <i>Proc. Natl. Acad. Sci. USA</i> 82:2115-2119 (1985).	
STF		CHAN, et al., "Ribonucleoprotein SS-B/La belongs to a Protein Family with Consensus Sequences for RNA Binding," <i>Nucl. Acids Res.</i> 17:2233-2244 (1989).	
STF		COHEN, "The Self, the World and Autoimmunity - Autoimmunity - In Which the Immune System Recognizes and Attacks the Self's Own Tissues - Is Not as Simple as it Seemed. Self-recognition Appears to be at the Heart of Health as Well as of Certain Diseases," <i>Scientific American</i> 258:52-60 (1988).	
STF		CRAFT, et al., "MURINE and Drosophila B Proteins of SM snRNPS," <i>Mol. Biol. Rep.</i> 15:159 (1991).	

Examiner's Signature	<i>Sharon Folg</i>	Date Considered	12/26/00
----------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b> Application Number <b>09/500,904</b> Filing Date <b>February 9, 2000</b> First Named Inventor <b>John B. Harley</b> Group Art Unit Examiner Name Attorney Docket Number <b>OMRF 161 CIP</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Sheet <b>5</b> of <b>23</b>	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
OIP E APR 20 2000 PATENT & TRADEMARK OFFICE	SAF	CRONE, et al., "Viral Transcription is Necessary and Sufficient for Vesicular Stomatitis Virus to Inhibit Maturation of Small Nuclear Ribonucleoproteins," <i>Journal of Virology</i> 63(10):4172-4180 (1989).	
	SAF	GUNNINGHAM, et al., "Human Monoclonal Antibodies Reactive with Antigens of the Group A Streptococcus and Human Heart," <i>Journal of Immunology</i> 141(8):2760-2766 (1988).	
	SAF	DALLDORF, et al., "The Lymphomas of Brazilian Children," <i>J. Am. Med. Assn.</i> 208:1365-8 (1969).	
	SAF	DEACON, et al., "Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome," <i>J. Pathol.</i> 163:351-360 (1991).	
	SAF	DEACON, et al., "Frequency of EBV DNA Detection in Sjogren's Syndrome," <i>Am J. Med.</i> 92:453-454 (1992).	
	SAF	DEPOLO, et al., "Continuing Coevolution of Virus and Defective Interfering Particles and of Viral Genome Sequences During Undiluted Passages: Virus Mutants Exhibiting Nearly Complete Resistance to Formerly Dominant Defective Interfering Particles," <i>J. of Virology</i> 61:454-464 (1987).	
	SAF	DEUTSCHER, et al., "Molecular Analysis of the 60-kDa Human Ro Ribonucleoprotein," <i>Proc. Natl. Acad. Sci. USA</i> 85:9479-83 (1988).	
		<del>DICKEY, "Human Autoantibody Producing Grafts in SCID Mice," presented to the Oklahoma Lupus Association, Inc., Sept. 1, 1989.</del>	
SAF	DYRBERG & OLDSTONE, "Peptides as Probes to Study Molecular Mimicry and Virus-Induced Autoimmunity," <i>Current Topics in Microbiology and Immunology</i> 130:25-37 (1986).		
SAF	ELKON, et al., "Epitope Mapping of Recombinant HeLa SmB and B' Peptides Obtained by the Polymerase Chain Reaction," <i>J. Immun.</i> 145:636-643 (1990).		

Examiner's Signature	<i>Shannon Fob</i>	Date Considered	<i>12/26/00</i>
----------------------	--------------------	-----------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		<b>Complete if Known</b>	
		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 6 of 23	Attorney Docket Number	OMRF 161 CIP	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SHF	ESQUIVEL, et al., "Induction of Autoimmunity in Good and Poor Responder Mice with Mouse Thyroglobulin and Lipopolysaccharide," <i>J. Exp. Med.</i> 145:1250-1263 (1977).		
SHF	EVANS & NIEDERMAN, "Epstein-Barr virus". in <i>Viral Infections in Humans</i> , 3rd ed. Evans, A.S. ed. pp 265-292 Plenum, New York City 1989).		
SHF	EVANS & ROTHFIELD, "E.B. Virus and Other Viral Antibodies in Systemic Lupus Erythematosus," <i>Lancet</i> 1:1127-1128 (1973).		
SHF	EVANS, "E.B. Virus Antibody in Systemic Lupus Erythematosus" <i>Lancet</i> 1:1023-4 (1971).		
SHF	EVANS, et al., "E.B.V. Antibodies in Systemic Lupus Erythematosus," <i>Lancet</i> 325-324 (1973).		
SHF	EVANS, et al., "Raised Antibody Titres to E.B. Virus in Systemic Lupus Erythematosus," <i>Lancet</i> 1:167-168 (1971).		
SHF	FERRIS & DONALDSON, <i>Veterinary Microbiology</i> 18(3-4):243-258 (1988).		
SHF	FINERTY, et al., "Immunization of Cottontop Tamarins and Rabbits with a Candidate Vaccine Against the Epstein-Barr Virus Based on the Major Viral Envelope Glycoprotein gp340 and Alum," <i>Vaccine</i> 12:1180-1184 (1994).		
SHF	FINERTY, et al., "Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope glycoprotein gp340 Produced from a Bovine Papillomavirus Expression Vector," <i>J. Gen. Virol.</i> 73:449-453 (1992).		
SHF	FOX, "Sjogren's Syndrome," <i>Current Opin. Rheum.</i> 7:409-416 (1995).		

Examiner's Signature	<i>Shawn Foley</i>	Date Considered	12/26/00
----------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		<b>Complete if Known</b>	
		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 7 of 23	Attorney Docket Number	OMRF 161 CIP	

**OTHER ART – NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SAF		FOX, et al., "Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's Syndrome," <i>J. Immunol.</i> 137:3162-3168 (1986).	
SAF		FOX, et al., "Potential Role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis," <i>J. Rheumatol.</i> 19:18-24 (1992).	
SAF		FRICKE, et al., "Induction of Experimental Systemic Lupus Erythematosus in Mice by Immunization with a Monoclonal Anti-La Autoantibody," <i>Intern. Immunol.</i> 2:225-230 (1990).	
SAF		FRITZ, et al., "Small Nuclear U-Ribonucleoproteins in <i>Xenopus Laevis</i> Development," <i>J. Mol. Biol.</i> 178:273-285 (1984).	
SAF		GAITHER, et al., "Implications of Anti-Ro/Sjogren's Syndrome a Antigen Autoantibody in Normal Sera for Autoimmunity," <i>J. Clin. Invest.</i> 79:841-846 (1987).	
SAF		GAITHER, et al., "Affinity Purification and Immunoassay of Anti-Ro/SSA" <i>Peptides Biol. Fluids</i> 33:413-416 (1985).	
SAF		GALLIONE, et al., "Nucleotide Sequences of the mRNA's Encoding the Vesicular Stomatitis Virus N and NS Proteins," <i>Virology</i> 39:529-535 (1981).	
SAF		*GAUTAM, et al., "A viral peptide with limited homology to a self peptide can induce clinical signs of experimental autoimmune encephalomyelitis," <i>J. Immunol.</i> 161:60-64 (1998).	
SAF		GERGELY, et al., "E.B.V. Antibodies in Systemic Lupus Erythematosus," <i>Lancet</i> 1:325-326 (1973).	
		<del>GEYSEN, et al., "Strategies for Epitope Analysis Using Peptide Synthesis," <i>J. of Immunol. Meth.</i> 102:259-274 (1987).</del>	

Examiner's Signature	<i>Shuman Tef</i>	Date Considered	12/6/00
----------------------	-------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 8 of 23	Attorney Docket Number	OMRF 161 CIP	

**OTHER ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SFF		GEYSEN, et al., "Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid," <i>Proc. Natl. Acad. Sci. USA</i> 81:3998-4002 (1984).	
SFF		GRABOWSKI, et al., "Drosophila AP3, a Presumptive DNA Repair Protein, is Homologous to Human Ribosomal Associated Protein PO," <i>Nucleic Acids Research</i> 19(15):4297 (1991).	
SFF		et al., "First EBV Vaccine Trial in Humans Using Recombinant Vaccinia Virus Expressing the Major Membrane Antigen," <i>Dev. Biol. Stand.</i> 84:171-177 (1995).	
SFF		GULDNER, et al., "Epitope mapping with a recombinant human 68-kDa (U1) ribonucleoprotein antigen reveals heterogeneous autoantibody profiles in human autoimmune sera." <i>The Journal of Immunology</i> 141(2):469-475 (1988).	
SFF		GUTIERREZ, et al., "Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia," <i>Cancer Res.</i> 56:969-972 (1996).	
SFF		HAAHR, et al., "A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in This Disease," <i>Ann. N. Y. Acad. Sci.</i> 724:148-156 (1996).	
SFF		HAHN, "Suppression of Autoimmune Diseases with Anti-idiotypic Antibodies: Murine Lupus Nephritis as a Model" <i>Springer Seminars in Immunopathology</i> , 7(1):25-34 (1984).	
SFF		HARDGRAVE, et al, "Antibodies to Vesicular Stomatitis Virus Proteins in Patients with Systemic Lupus Erythematosus and in Normal Subjects," <i>Arthritis and Rheumatism</i> 36(7):962-970 (1993).	
SFF		HARLEY & GAITHER, "Autoantibodies" <i>Rheum. Dis. Clin. N. Amer.</i> 14:43-56 (1992).	
SFF		HARLEY & JAMES, "Review Articles: Autoepitopes in Lupus," <i>J. Lab. Clin Med.</i> 126(6):509-516 (1995).	

Examiner's Signature	<i>Sharon Foley</i>	Date Considered	12/26/00
----------------------	---------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		<b>Complete if Known</b>	
		<p>Application Number</p> <p>09/500,904</p>	
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	9	of	23
		Attorney Docket Number	OMRF 161 CIP

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SH		HARLEY, et al., "Epstein-Barr virus infection may be an environmental risk factor for systemic lupus erythematosus in children and teenagers," <i>Arthritis Rheum.</i> 42(8):1782-3 (1999).	
SH		HARLEY, et al., "Gene Interaction at HLA-DQ Enhances Autoantibody Production in Primary Sjogren's Syndrome," <i>Science</i> 232:1145-1147 (1986).	
SH		HARLEY, et al., "Anti-Ro (SS-A) and Anti-La (SS-B) in Patients with Sjogren's Syndrome," <i>Arthritis Rheum.</i> 29:196-198 (1986).	
SH		HERBERT, et al., Dictionary of Immunology 3 <sup>rd</sup> Ed. Blackwell Scientific Publications Oxford UK page 14 (1985).	
SH		HESLOP, et al., "Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes," <i>Nature Med.</i> 2:551-555 (1996).	
SH		HINTERBERGER, "Isolation of Small Nuclear Ribonucleoproteins Containing U1, U2, U4, U5, and U6 RNAs," <i>J. Biol. Chem.</i> 258:2604-2613 (1983).	
SH		HOLLINGER, et al., "Seroepidemiologic Studies in Systemic Lupus Erythematosus," <i>Bact. Proc.</i> 131:174 (1970).	
SH		HORSFALL, et al., "Ro and La Antigens and Maternal Anti-La Idiotype on the Surface of Myocardial Fibers in Congenital heart Block," <i>J. of Autoimmun.</i> 4:165-176 (1991).	
SH		HUANG, et al., "Human Anti-Ro Autoantibodies Bind Peptides Accessible to the Surface of the Native Ro Autoantigen," <i>Scand. J. Immunol.</i> 41:220-228 (1995).	
SH		HUANG, et al., "Immunization with Vesicular Stomatitis Virus Nucleocapsid Protein induces Autoantibodies to the 60 kD Ro Ribonucleoprotein Particle," <i>J. Invest. Med.</i> 43:151-158 (1995).	

Examiner's Signature	<i>Sharon F. [Signature]</i>	Date Considered	12/26/00
----------------------	------------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 10 of 23	Attorney Docket Number	OMRF 161 CIP	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SHF	13:724-733 (1970)	MURD, et al., "Formation of Leukocyte Inclusions in Normal Polymorphonuclear Cells Incubated with Synovial Fluid," <i>Arthritis Rheum.</i> 13:724-733 (1970).	
SHF	164:22-28 (1991)	INOUE, et al., "Analysis of Antibody Titers to Epstein-Barr Virus Nuclear Antigens in Sera of Patients with Sjogren's Syndrome and with Rheumatoid Arthritis," <i>J. Infect. Dis.</i> 164:22-28 (1991).	
SHF	73:463-468 (1995)	SHILL, et al., "Cycloheximide-Induced Apoptosis in Burkitt Lymphoma (BJA-B) Cells with and Without Epstein-Barr Virus Infection," <i>Immunol. Cell Biol.</i> 73:463-468 (1995).	
SHF	4018-4026 (1994)	JAMES & HARLEY, "Human Lupus Anti-Spliceosome A Protein Autoantibodies Bind Contiguous Surface Structures and Segregate into Two Sequential Epitope Binding Patterns," <i>J. Immunol.</i> 4018-4026 (1994).	
SHF	148:2074-2079 (1992)	JAMES & HARLEY, "Linear Epitope Mapping of an Sm B/B' Polypeptide," <i>J. Immunol.</i> 148:2074-2079 (1992).	
SHF	13:299-305 (1995)	JAMES & HARLEY, "Peptide Autoantigenicity of the Small Nuclear Ribonucleoprotein C," <i>Clin. And Exp. Rheum.</i> 13:299-305 (1995).	
SHF	41(2):PA393 (1993)	JAMES & HARLEY, "Sequential Fine Specificity of the Small Nuclear Ribonuclear Protein C," <i>Clinical Res.</i> 41(2):PA393 (1993).	
SHF	160(1):502-8 (1998)	*JAMES & HARLEY, "A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice," <i>J. Immunol.</i> 160(1):502-8 (1998).	
SHF	100:3019-26 (1997)	*JAMES, et al., "An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus," <i>J. Clin. Invest.</i> 100:3019-26 (1997).	
SHF	815:124-7 (1997)	*JAMES, et al., "Lupus humoral autoimmunity after short peptide immunization," <i>Ann. N. Y. Acad. Sci.</i> 815:124-7 (1997).	

Examiner's Signature	<i>Sham 7ef</i>	Date Considered	12/26/00
----------------------	-----------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 11 of 23	Attorney Docket Number	OMRF 161 CIP	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SHF		JAMES, et al., "Immunoglobulin Epitope Spreading and Autoimmune Disease After Peptide Immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP Induce Spliceosome Autoimmunity," <i>J. Exp. Med.</i> 181:453-461 (1995).	
SHF		JAMES, et al., "Basic Amino Acids Predominate in the Sequential Autoantigenic Determinants of the Small Nuclear 70K Ribonucleoprotein," <i>Scand. J. Immunol.</i> 39:557-566 (1994).	
SHF		JAMES, et al., "Inbred Mice Strains Differ in Their Capacity to Develop Spliceosomal Autoimmunity After Peptide Immunization," <i>Arthritis Rheum.</i> 38:S226 (1995).	
SHF		JAMES, et al., "Lupus Humoral Autoimmunity After Short Peptide Immunization," <i>Arthritis Rheum.</i> 39:S216 (1996).	
SHF		JAMES, et al., "Sequential Autoantigenic Determinants of the Small Nuclear Ribonucleoprotein Sm D Shared by Human Lupus Autoantibodies and MRL <i>lpr/lpr</i> Antibodies," <i>Clin. Exp. Immunol.</i> 98:419-426 (1994).	
		<del>KALUSH, et al., "Neonatal Lupus Erythematosus with Cadian Involvement in Offspring of Mothers with Experimental Systemic Lupus Erythematosus," <i>J. of Clin. Immunol.</i> 14:314-321 (1994).</del>	
SHF		KARAMERIS, et al., "Detection of the Epstein Barr Viral Genome by an <i>in situ</i> Hybridization Method in Salivary Gland Biopsies from Patients with Secondary Sjogren's Syndrome," <i>Clin. Exp. Rheum.</i> 10:327-332 (1992).	
SHF		KAUFMAN, et al., "In Vivo Binding of Gram-Negative Bacterial Peptides to Hla-B27: A Possible Relationship to Ankylosing spondylitis Pathogenesis," <i>Arthritis Rheum.</i> 39:S298 (1996)	
SHF		KIEFF & LIEBOWITZ, Epstein-Barr virus and its replication. In <i>Virology</i> , 2nd ed. Fields et al., eds. pp 1889-1921 (Raven Press, New York 1990).	
SHF		KITAGAWA, et al., "Detection of Antibodies to the Epstein-Barr Virus Nuclear Antigens in the Sera from Patients with Systemic Lupus Erythematosus," <i>Immunol. Lett.</i> 17:249-252 (1988).	


Examiner's Signature	<i>Shawn A. Kelly</i>	Date Considered	12/26/00
----------------------	-----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>		<b>Complete if Known</b>	
		<b>Application Number</b>	<b>09/500,904</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Filing Date</b>	<b>February 9, 2000</b>
		<b>First Named Inventor</b>	<b>John B. Harley</b>
		<b>Group Art Unit</b>	
		<b>Examiner Name</b>	
		<b>Attorney Docket Number</b>	<b>OMRF 161 CIP</b>
Sheet	12	of	23

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SH		KLIPPEL, et al., "Epstein-Barr Virus Antibody and Lymphocyte Tubuloreticular Structures in Systemic Lupus Erythematosus," <i>Lancet</i> , 2:1057-1058 (1973).	
SH		KURILLA, et al., "The Leader RNA of Vesicular Stomatitis Virus is Bound by a Cellular Protein Reactive with Anti-La Lupus Antibodies," <i>Cell</i> 34:837-845 (1983).	
SH		KUZUSHIMA, et al., "Establishment of Anti-Epstein-Barr Virus (EBV) Cellular Immunity by Adoptive Transfer of Virus-Specific Cytotoxic T Lymphocytes from an HLA-matched Sibling to a Patient with Severe chronic Active EBV Infection," <i>Clin. Exp. Immunol.</i> 103:192-198 (1996).	
SH		LARSEN, et al., "Epstein-Barr Nuclear Antigen and Viral Capsid Antigen Antibody Titers in Multiple Sclerosis," <i>Neurology</i> 35:435-438 (1985).	
SH		LAZAROVITS, et al., "Anti-B Cell Antibodies for the Treatment of Monoclonal Epstein-Barr Virus-Induced Lymphoproliferative Syndrome After Multivisceral Transplantation," <i>Clin. Invest. Med.</i> 17:621-625 (1994).	
SH		LEE, et al., "Cardiac Immunoglobulin Deposition in Congenital heart Block Associated with Maternal Anti-Ro Autoantibodies," <i>Am. J. of Med.</i> 83:793-796 (1987).	
SH		LEE, et al., "The Recognition of Human 60-kDa Ro Ribonucleoprotein Particles by Antibodies Associated with Cutaneous Lupus and Neonatal Lupus," <i>J. Investigative Dermatology</i> 107(1):225-228 (1996).	
SH		LEFF, "Maverick Herpes Receptor Sparks Search for KS Drug," <i>Bio World Today</i> 8(17):1 (1997).	
		<del>LEHMAN, et al., "Spreading of T-Cell Autoimmunity to Cryptic Determinants of an Autoantigen," <i>Nature</i> 356:155-157 (1992).</del>	
		<del>LERNER &amp; STEITZ, "Antibodies to Small Nuclear PNAs Complexed with Proteins are Produced by Patients with Systemic Lupus Erythematosus," <i>Proc. Natl. Acad. Sci. USA</i> 76:5495-5499 (1979).</del>	


Examiner's Signature		Date Considered	12/26/00
----------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				<p>Application Number <b>09/500,904</b></p>	
<p>Filing Date <b>February 9, 2000</b></p>		<p>First Named Inventor <b>John B. Harley</b></p>		<p>Group Art Unit</p>	
<p>Examiner Name</p>		<p>Attorney Docket Number <b>OMRF 161 CIP</b></p>			
Sheet	13	of	23		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SAF		LERNER, et al., "Are snRNPs Involved in Splicing?" <i>Nature</i> 283:220-224 (1980).	
SAF		LEVITSKAYA, "Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1," <i>Nature</i> 375:685-688 (1995).	
SAF		MADDISON, et al., "Quantitation of Precipitating Antibodies to Certain Soluble Nuclear Antigens in SLE," <i>Arthritis Rheum.</i> 20:819-824 (1977).	
SAF		MAITLAND, "Frequency of EBV-DNA Detection in Sjogren's Syndrome," <i>Am. J. Med.</i> 96:97 (1994).	
SAF		MANFREDI, et al., "Molecular Anatomy of an Autoantigen: T and B Epitopes on the Nicotinic Acetylcholine Receptor in Myasthenia Gravis," <i>J. Lab. Clin. Med.</i> 120:13-21 (1992).	
SAF		MARIETTE, et al., "Detection of Epstein-Barr Virus DNA by <i>in Situ</i> Hybridization and Polymerase Chain Reaction in Patients with Sjogren's Syndrome," <i>Am. J. Med.</i> , 90:286-294 (1991).	
SAF		MATTER, et al., "Molecular Characterization of Ribonucleoprotein Antigens Bound by Antinuclear Antibodies," <i>Arthritis Rheum.</i> 25:1278-1283 (1982).	
SAF		MATTIOLI, et al. "Physical Association of Two Nuclear Antigens and Mutual Occurrence of Their Antibodies: The relationship of the SM and RNA protein (MO) Systems in SLE Sera," <i>J. Immunol.</i> 110:1318-1324 (1973).	
SAF		MCALLISTER, et al., "cDNA Sequence of the rat U snRNP-associated Protein N: Description of a Potential Sm Epitope," <i>EMBO J.</i> 8:1177-1181 (1989).	
SAF		MENDLOVIC, et al., "Induction of an SLE-Like Disease in Mice by a Common Anti-DNA Idiotypic," <i>Proc. Natl. Acad. Sci. USA</i> 85:2260-2264 (1988).	

Examiner's Signature	<i>Shannon Foley</i>	Date Considered	12/26/00
----------------------	----------------------	-----------------	----------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/500,904		
		Filing Date	February 9, 2000		
		First Named Inventor	John B. Harley		
		Group Art Unit			
		Examiner Name			
Sheet	14	of	23	Attorney Docket Number	OMRF 161 CIP

**OTHER ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SAF		MENDLOVIC, et al., "The Genetic Regulation of the Induction of Experimental SLE," <i>Immunology</i> 69:228-236 (1990).	
SAF		MENDLOVIC, et al., "The Role of Anti-Idiotypic Antibodies in the Induction of Experimental Systemic Lupus Erythematosus in Mice," <i>Eur. J. Immunol.</i> 19:729-732 (1989).	
SAF		MILLER, et al., "The Role of an Autoantigen, Histidyl-tRNA Synthetase, in the Induction and Maintenance of Autoimmunity," <i>Proc. Natl. Acad. Sci. USA</i> 87:9933-9937 (1990).	
SAF		MIYASHITA, et al., "A Novel Form of Epstein-Barr Virus Latency in Normal B Cells In Vivo," <i>Cell</i> , 80:593-601 (1995).	
SAF		MORGAN, "Epstein-Barr Virus Vaccines," <i>Vaccine</i> 10:563-571 (1992).	
SAF		MORGAN, et al., "Validation of a First-Generation Epstein-Barr Virus Vaccine Preparation Suitable for Human Use," <i>J. Med. Virol.</i> 29:74-78 (1989).	
SAF		MORLAND, et al., "Anti-idiotypic and Immunosuppressant Treatment of Murine Lupus," <i>Clin. Exp. Immunol.</i> 83(1):126-132 (1991).	
SAF		MORSHED, et al., "Increased Expression of Epstein-Barr Virus in Primary Biliary Cirrhosis Patients," <i>Gastroenterol. Jpn.</i> 27(6):751-758 (1992).	
SAF		MOSIER, et al., "Transfer of a functional human immune system to mice with severe combined immunodeficiency," <i>Nature</i> 335:256-259 (1988).	
SAF		MUNVES, et al., "Antibodies to Sm and RNP," <i>Arthritis Rheum.</i> 26:848-853 (1983).	

Examiner's Signature		Date Considered	12/26/00
----------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	09/500,904
				Filing Date	February 9, 2000
				First Named Inventor	John B. Harley
				Group Art Unit	
				Examiner Name	
Sheet	15	of	23	Attorney Docket Number	OMRF 161 CIP

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SAF		*NICHOLSON, "A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens," <i>Proc. Natl. Acad. Sci. USA</i> 94:9279-9284 (1997).	
SAF		NEWELL & STEVENS, "E.B. Virus Antibody in Systemic Lupus Erythematosus," <i>Lancet</i> 1:652 (1971).	
SAF		NEWKIRK, et al., "Detection of Cytomegalovirus, Epstein-Barr Virus and Herpes Virus-6 in Patients with Rheumatoid Arthritis With or Without Sjogren's Syndrome," <i>Br. J. Rheum.</i> 33:317-322 (1994).	
SAF		OHOSONE, et al., "Molecular Cloning of cDNA Encoding Sm Autoantigen: Derivation of a cDNA for a B Polypeptide of the U Series of Small Nuclear Ribonucleoprotein Particles," <i>Proc. Natl. Acad. Sci. USA</i> 86:4249-4253 (1989).	
SAF		PALFI, et al, "Purification of the Major UsnRNPs from Broad Bean Nuclear Extracts and Characterization of their Protein Constituents," <i>Nucleic Acids Res.</i> 17:1445-1458 (1989).	
SAF		PETERSEN, et al, "Altered Immune Response to Glycine-Rich Sequences of Epstein-Barr Nuclear Antigen-1 in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 33:993-1000 (1990).	
SAF		PETTERSSON, et al., "The Structure of Mammalian Small Nuclear Ribonucleoproteins," <i>J. Biol. Chem.</i> 259:5907-5914 (1984).	
SAF		PFLUGFELDER, et al., "Amplification of Epstein-Barr Virus Genomic Sequences in Blood Cells, Lacrimal Glands, and Tears from Primary Sjogren's Syndrome Patients," <i>Ophthalmology</i> 97:976-984 (1990).	
SAF		PFLUGFELDER, et al., "Epstein-Barr Virus and the Lacrimal Gland Pathology of Sjogren's Syndrome," <i>Am. J. Pathol.</i> 143:49-64 (1993).	
		PHILLIPS & CHRISTIAN, "Myxovirus Antibody Increases in Human Connective Tissue Disease," <i>Science</i> 168:982-4 (1970).	

Examiner's Signature	<i>Shawn Feltz</i>	Date Considered	12/26/00
----------------------	--------------------	-----------------	----------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	09/500,904
				Filing Date	February 9, 2000
				First Named Inventor	John B. Harley
				Group Art Unit	
				Examiner Name	
Sheet	16	of	23	Attorney Docket Number	OMRF 161 CIP

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SAF		PHILLIPS, et al., "Viruses and Systemic Lupus Erythematosus," <i>Lancet</i> 1:1449 (1973).	
SAF		QUALTIERE & PEARSON, "Radioimmune Precipitation Study Comparing the Epstein-Barr Virus Membrane Antigens Expressed on P3HR-T Virus-Superinfected Raji Cells to those Expressed on Cells in a B-95 Virus-Transformed Produced Culture Activated with Tumor-Promoting Agent (TPA)," <i>Virology</i> 102:360-369 (1980).	
SAF		QUERY, et al., "A Common RNA Recognition Motif Identified within a Defined U1 RNA Binding of the 70K U1 snRNP Protein," <i>Cell</i> 57:89-101 (1989).	
SAF		RAVIRAJAN & STAINES, "Involvement in Lupus Disease of Idiotypes Id.F-423 and Id.IV-228 Defined, Respectively, Upon Foetal and Adult MRL/Mp-lpr/lpr DNA-binding Monoclonal Autoantibodies" <i>Immunology</i> 74:342-347 (1991).	
SAF		REICHLIN, et al., "Autoantibodies to the URNP Particles: Relationship to Clinical Diagnosis and Nephritis," <i>Clin. Exp. Immunol.</i> 83:286-290 (1991).	
SAF		REICHLIN, et al., "Concentration of Autoantibodies to native 60-kd Ro/SS-A and Denatured 52-kd Ro/SS-A in Eluates from the Heart of a Child Who Died with Congenital Complete Heart Block," <i>Arth. And Rheum.</i> 37:1698-1703 (1994).	
SAF		RENZ, et al., "Expression of the Major Human Ribonucleoprotein (RNP) Autoantigens in <i>Escherichia coli</i> and their Use in an EIA for Screening Sera from Patients with Autoimmune Diseases," <i>Clin. Chem.</i> 35:1861-1863(1989).	
SAF		REUTER, et al., "Immunization of Mice with Purified U1 Small Nuclear Ribonucleoprotein (RNP) Induces a Pattern of Antibody Specificities Characteristic of the Anti-Sm and Anti-RNP Autoimmune Response of Patients with Lupus Erythematosus, As Measured by Monoclonal Antibodies," <i>PNAS</i> 83:8689-8693 (1986).	
SAF		RHODES, et al., "Autoantibodies in Infectious Mononucleosis Have Specificity for the Cyclic-Alanine Repeating Region of the Epstein-Barr Virus Nuclear Antigen," <i>J. Exp. Med.</i> , 165:1026-1040 (1987).	
SAF		RHODES, et al., "Human Immune Responses to Synthetic Peptides from the Epstein-Barr Nuclear Antigen," <i>J. Immunol.</i> 134:211-216 (1985).	

Examiner's Signature		Date Considered	12/26/00
----------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/500,904		
		Filing Date	February 9, 2000		
		First Named Inventor	John B. Harley		
		Group Art Unit			
		Examiner Name			
Sheet	17	of	23	Attorney Docket Number	OMRF 161 CIP

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SAF		ROKEACH, et al., "Primary Structure of a Human Small Nuclear Ribonucleoprotein Polypeptide as Deduced by cDNA Analysis," <i>J. Biol. Chem.</i> , 264:5024-30 (1989).	
SAF		ROKEACH, et al., "Molecular Cloning of a cDNA Encoding the Human Sm-D Autoantigen," <i>Proc. Natl. Acad. Sci. USA</i> 85:4832-36 (1988).	
SAF		ROSE, et al., "Genetic Regulation in Autoimmune Thyroiditis," Talal N. ed. <i>Autoimmunology Genetic Immunologic Virologic, and Clinical Aspects</i> . New York: Academic Press, 63-87 (1977).	
SAF		ROSE, et al., "Studies on Experimental Thyroiditis," <i>Ann. NY Acad. Sci.</i> 124:201-209 (1965).	
SAF		ROSE, et al., "T-Cell Regulation in Autoimmune Thyroiditis," <i>Immunol. Reviews</i> 55:229-314 (1981).	
SAF		SABBATINI, et al., "Autoantibodies from Patients with Systemic Lupus Erythematosus Bind a Shared Sequence of AmD and Epstein-Barr Virus-Encoded Nuclear Antigen EBNA 1," <i>Eur. J. Immunol.</i> 23:1146-1152 (1993).	
SAF		SAITO, et al., "Detection of Epstein-Barr Virus DNA by Polymerase Chain Reaction in Blood and Tissue Biopsies from Patients with Sjogren's Syndrome," <i>J. Exp. Med.</i> , 169:2191-2198 (1989).	
SAF		SASAKI, et al., "In Vitro Manipulation of Human Anti-DNA Antibody Production by Anti-idiotypic Antibodies Conjugated with Neocarzinostatin," <i>The Journal of Immunology</i> 142(4):1159-1165 (1989).	
SAF		SCHAAK, "Molecular Mimicry in HLA-B-27-Related Arthritis," <i>Annals of Internal Medicine</i> 111(7):581-591 (1989).	
SAF		SCHMAUSS, et al., "A Comparison of snRNP-Associated Sm-Autoantigens: Human N, Rat N and Human B/B (abstract)," <i>Nuc. Acid Res.</i> 17:1733-43 (1989).	

Examiner's Signature		Date Considered	12/26/00
----------------------	--	-----------------	----------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				<b>Complete if Known</b>		
				Application Number		09/500,904
				Filing Date		February 9, 2000
				First Named Inventor		John B. Harley
				Group Art Unit		
				Examiner Name		
Sheet	18	of	23	Attorney Docket Number		OMRF 161 CIP

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SAF		SCOFIELD, "HLA-B27 Binding of Peptide From Its Own Sequence and Similar Peptides From Bacteria: Implications For Spondyloarthropathies," <i>Lancet</i> , 345:1542-1544 (1995).	
SAF		SCOFIELD, "A Common Autoepitope Near the carboxyl Terminus of the 60-kD Ro Ribonucleoprotein: Sequence Similarity with a Viral Protein," <i>Journal of Clinical Immunology</i> 11(6):378-388 (1991).	
SAF		SCOFIELD, "Autoimmune Thyroid Disease in Systemic Lupus Erythematosus and Sjogren's Syndrome," <i>Clin. Exp. Rheum.</i> 14:321-330 (1996).	
SAF		SCOFIELD, et al., "Immunization with Short Peptides from the Sequence of the Systemic Lupus Erythematosus-Associated 60-kDa Ro Autoantigen Results in Anti-Ro Ribonucleoprotein Autoimmunity," <i>J. Immunology</i> 4059-4066 (1996).	
SAF		SCOFIELD, et al., "Autoantigenicity of Ro/SSA Antigen is Related to a Nucleocapsid Protein of Vesicular Stomatitis Virus," <i>Proc. Natl. Acad. Sci. USA</i> , 88:3343-3347 (1991).	
SAF		SCOFIELD, et al., "Development of the Anti-Ro Autoantibody Response in a Patient with Systemic Lupus Erythematosus," <i>Arthritis &amp; Rheumatism</i> 39(10):1664-1688 (1996).	
SAF		SCOFIELD, et al., "The Autoantigenicity of Human 60kD Ro/SSA is Related to Homologies Between Ro/SSA and the Nucleocapsid Protein of Vesicular Stomatitis Virus," <i>Clinical Research</i> 38(2):316A, (1990).	
SAF		SCULLEY, et al., "Reactions of Sera from Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Infectious Mononucleosis to Epstein-Barr Virus-Induced Polypeptides," <i>J. Gen. Virol.</i> 67:2253-2258 (1986).	
SAF		SHARPE, et al., "Isolation of cDNA Clones Encoding the Human Sm B/B' Auto-Immune Antigen and Specifically Reaching with Human Anti-Sm Auto-," <i>FEBS Lett.</i> 250:585-590 (1989).	
SAF		SHOENFELD, et al. "Modulation of experimental SLE induced in naïve mice by a pathogenic anti-DNA idiotype (16/6 Id.)," <i>Proceedings of the Second International Conference on Systemic Lupus Erythematosus Tokyo, Japan Professional Postgraduate Services</i> 83 (1989).	


Examiner's Signature	<i>Sharon Felt</i>	Date Considered	12/26/00
----------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	
				09/500,904	
				Filing Date	
				February 9, 2000	
				First Named Inventor	
				John B. Harley	
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	
				OMRF 161 CIP	
Sheet	19	of	23		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		SHOENFELD, et al., "Pathogenic idiotypes of autoantibodies in autoimmunity: lessons from new experimental models of SLE," <i>FASEB J.</i> 4:2646-2651 (1990).	
SAF		SILLIKENS, et al., "cDNA Cloning of the Human U1 snRNA-Associated A Protein: Extensive Homology Between U1 and U2 snRNP-Specific Proteins," <i>EMBO Journal</i> 6:3841-3848 (1987).	
SAF		SILLIKENS, et al., "Human U1 snRNP-specific C Protein: Complete cDNA and Protein Sequence and Identification of a Multigene Family in Mammals," <i>Nucleic Acids Res.</i> 16:8307-21 (1988).	
SAF		SINGH, et al., "Decreased Incidence of Viral Infections in Liver Transplant Recipients - Possible Effects of FK506?," <i>Digestive Dis. Sci.</i> 39:15-18 (1994).	
SAF		SPRITZ, et al., "The Human U1-70K s.n. RNP-Protein: cDNA Cloning, Chromosomal Localization, Expression, Alternative Splicing and RNA-binding," <i>Nucleic Acid Res.</i> 15:10373-91 (1987).	
SAF		STURGESS, et al., "Characteristics and Epitope Mapping of a Cloned Human Autoantigen La," <i>J. Immun.</i> 3212-3218 (1988).	
SAF		SUMAYA, et al., "Increased Prevalence and Titer of Epstein-Barr Virus Antibodies in Patients with Multiple Sclerosis," <i>Ann. Neurol.</i> 17:371-377 (1985).	
SAF		SUZUKI, et al., "Viral Interleukin 10 (IL-10), the Human Herpes Virus 4 Cellular IL-10 Homologue, Induces Local Anergy to Allogeneic and Syngeneic Tumors," <i>J. Exp. Med.</i> 182:477-486 (1995).	
SAF		TAKEDA, et al., "Antigenic Domains on the U1 Small Nuclear Ribonucleoprotein-associated 70kD Polypeptide; a comparison of regions selectively recognized by Human and Mouse Autoantibodies and by Monoclonal Antibodies," <i>Chem. Abstracts</i> 116(1): ab. No. 4803a (January 6, 1992).	
SAF		TAN, et al., "The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 25:1271-1277 (1982).	


Examiner's Signature		Date Considered	12/26/00
----------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 20 of 23	Attorney Docket Number	OMRF 161 CIP	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SAF		TAN, et al., "Characteristics of a Soluble Nuclear Antigen Precipitating with Sera of Patients with Systemic Lupus Erythematosus," <i>J. Immunol.</i> 96:464-471 (1966).	
SAF		TATEISHI, et al., "Spontaneous Production of Epstein-Barr Virus by B Lymphoblastoid Cell Lines Obtained from Patients with Sjogren's Syndrome," <i>Arthritis Rheum.</i> 36:827-835 (1993).	
SAF		The Medical Letter on Drugs and Therapeutics 37(951):55-57 (June 23, 1995).	
SAF		THEISSEN, et al., "Cloning of the Human cDNA for the U1 RNA-associated 70K Protein," <i>EMBO J.</i> 5:3209-17 (1986).	
SAF		TIGBE, Production of Human Rheumatoid Factors (RF) by SCID Mice Transplanted with Synovial Membrane Lymphocytes, presented at the Arthritis Foundation Fellows Conference, Amelia Island, Plantation, Florida, December 8-10 (1989).	
SAF		TINCANI, et al., "Induction of Experimental SLE in Naive Mice by Immunization with Human Polyclonal anti-DNA Antibody Carrying the 16/6 Idiotype," <i>Clinical and Exp. Rheum.</i> 11:129-134 (1993).	
SAF		TODA, et al., "Sjogren's syndrome (SS) and Epstein-Barr virus (EBV) reactivation," In <u>Lacrimal Gland, Tear Film, and Dry Eye Syndrome</u> . (D.A. Sullivan, ed.) pp 647-650 (Plenum Press, New York 1994).	
SAF		TSAL, et al., "Detection of Epstein-Barr Virus and Cytomegalovirus Genome in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Systemic Lupus Erythematosus," <i>Int. Arch. Allergy Immunol.</i> 106:235-240 (1995).	
SAF		TSUZUKA, et al., "Lupus Autoantibodies to Double-stranded DNA Cross-react with Ribosomal Protein S11," <i>J. Immunol.</i> 156:1668-1675 (1996).	
SAF		TZARTOS, et al., "The Main Immunogenic region of the Acetylcholine Receptor. Structure and Role in Myasthenia Gravis," <i>Autoimmunity</i> 8:259-270 (1991).	

Examiner's Signature	<i>Shawn Fly</i>	Date Considered	12/26/00
----------------------	------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/500,904		
		Filing Date	February 9, 2000		
		First Named Inventor	John B. Harley		
		Group Art Unit			
		Examiner Name			
Sheet	22	of	23	Attorney Docket Number	OMRF 161 CIP

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SFF		WARNER & CARP, "Multiple Sclerosis Etiology - an Epstein-Barr Virus Hypothesis," <i>Med. Hypotheses</i> 25:93-97 (1988).	
SFF		WATSON, et al., "Certain Properties Make Substances Antigenic," in <i>Molecular Biology of the Gene</i> , Fourth Edition, page 836, paragraph 3, (The Benjamin/Cummings Publishing Company, Menlo Park, 1987).	
SFF		WHITTINGHAM, et al., "Epstein-Barr Virus as an Etiological Agent in Primary Sjogren's Syndrome," <i>Med. Hypothesis</i> , 22:373-386 (1987).	
SFF		WILLIAMS, et al., "A Repeated Proline-rich Sequence in Sm B/B' and N is a Dominant Epitope Recognized by Human and Murine Autoantibodies," <i>J. Autoimmunity</i> 3:715-725 (1990).	
SFF		WILSON, et al., "Association of Lymphomatoid Granulomatosis With Epstein-Barr Viral Infection of B Lymphocytes and Response to Interferon- $\alpha$ 2b," <i>Blood</i> , 87:4531-4537 (1996).	
SFF		WINFIELD, et al., "Serologic Studies in patients with Systemic Lupus Erythematosus and Central Nervous System Dysfunction," <i>Arthritis Rheum.</i> 21:289-294 (1978).	
SFF		WITEBSKY, et al., "Chronic Thyroiditis and Autoimmunization," <i>J. Am. Med. Assoc.</i> 164:1439-1447 (1957).	
SFF		XIE & SNYDER, "Two Short Autoepitopes on the Nuclear Dot Antigen Are Similar to Epitopes Encoded by the Epstein-Barr Virus," <i>Proc. Natl. Acad. Sci.</i> 92:1639-1643 (1995).	
SFF		YAMAMOTO, et al., "Isolation and Characterization of a Complementary DNA Expressing Human U1 Small Nuclear Ribonucleoprotein C Polypeptide," <i>J. Immun.</i> 140:311-317 (1988).	
SFF		YOKOCHI, et al., "Hight Titer of Antibody to the Epstein-Barr Virus Membrane Antigen in Sera from Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus," <i>J. Rheumatol.</i> 16:1029-1032 (1989).	

Examiner's Signature		Date Considered	12/26/00
----------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

